BRPI0910198A2 - composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. - Google Patents

composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.

Info

Publication number
BRPI0910198A2
BRPI0910198A2 BRPI0910198A BRPI0910198A BRPI0910198A2 BR PI0910198 A2 BRPI0910198 A2 BR PI0910198A2 BR PI0910198 A BRPI0910198 A BR PI0910198A BR PI0910198 A BRPI0910198 A BR PI0910198A BR PI0910198 A2 BRPI0910198 A2 BR PI0910198A2
Authority
BR
Brazil
Prior art keywords
nucleotide
based agent
administration
treating
composition
Prior art date
Application number
BRPI0910198A
Other languages
English (en)
Inventor
Amotz Shemi
Original Assignee
Silenseed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silenseed Ltd filed Critical Silenseed Ltd
Publication of BRPI0910198A2 publication Critical patent/BRPI0910198A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
BRPI0910198A 2008-06-30 2009-06-28 composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. BRPI0910198A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12947708P 2008-06-30 2008-06-30
PCT/IB2009/052778 WO2010001325A2 (en) 2008-06-30 2009-06-28 Methods, compositions and systems for local delivery of drugs

Publications (1)

Publication Number Publication Date
BRPI0910198A2 true BRPI0910198A2 (pt) 2016-01-12

Family

ID=41130308

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910198A BRPI0910198A2 (pt) 2008-06-30 2009-06-28 composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.

Country Status (8)

Country Link
US (1) US8999945B2 (pt)
EP (1) EP2323630B1 (pt)
JP (1) JP2011526619A (pt)
CN (1) CN102137658A (pt)
AU (1) AU2009265170A1 (pt)
BR (1) BRPI0910198A2 (pt)
IL (1) IL210185A0 (pt)
WO (1) WO2010001325A2 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118238A2 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
JP5860409B2 (ja) * 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
CN103917202B (zh) 2011-09-14 2016-06-29 弗赛特影像5股份有限公司 眼插入件装置和方法
US9006199B2 (en) 2011-11-14 2015-04-14 Silenseed Ltd. Methods and compositions for treating prostate cancer
US20130122096A1 (en) 2011-11-14 2013-05-16 Silenseed Ltd. Compositions for drug delivery and methods of manufacturing and using same
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
CN102525935A (zh) * 2012-01-18 2012-07-04 上海交通大学医学院 一种纳米药物载体脑内递送方法
US8889642B2 (en) 2012-04-19 2014-11-18 Silenseed Ltd. Methods and compositions for RNAi-based cancer treatment
NL2009145C2 (en) * 2012-07-06 2014-01-07 Xeltis B V Implant.
CN102861341B (zh) * 2012-09-29 2015-06-17 张建祥 一种能高效负载核酸类药物的复合纳米载体及其制备方法
EP2911623B1 (en) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
WO2014076703A1 (en) 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
US10102441B2 (en) * 2013-02-07 2018-10-16 Vanderbilt University Methods for automatic segmentation of inner ear anatomy in post-implantation CT and applications of same
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
HUE029575T2 (en) * 2013-05-02 2017-03-28 Cardionovum Gmbh Surface-coated balloon
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
EP3011034B1 (en) 2013-06-17 2019-08-07 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
WO2014204728A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
CN103394127A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有中西医药的阴道模具材料
CN103394128A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有川芎的模具材料
MX2016007328A (es) 2013-12-12 2017-07-19 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
KR20160089530A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒ­ｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
AU2014362248A1 (en) 2013-12-12 2016-06-16 Massachusetts Institute Of Technology Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
RU2016138020A (ru) * 2014-02-26 2018-03-29 Этрис Гмбх Композиции для введения phk в желудочно-кишечный тракт
CN104027848B (zh) * 2014-06-24 2015-10-14 中国人民解放军第四军医大学 一种用于牙周组织的生物支架材料及其制备方法
WO2016009428A1 (en) * 2014-07-14 2016-01-21 Silenseed Ltd. Rna interference compositions targeting heat shock protein 90 and methods of use thereof
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
ES2756301T3 (es) 2014-08-19 2020-04-27 Univ California Implantes de administración localizada de fármacos y métodos de uso de los mismos
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3200806A4 (en) 2014-09-29 2018-05-02 Board of Regents of the University of Nebraska Nanofiber structures and methods of synthesis and use thereof
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
ES2731876T3 (es) * 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Anticuerpos de dominio sencillo contra antígenos intracelulares
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
RU2752834C2 (ru) 2015-06-18 2021-08-09 Те Брод Инститьют, Инк. Мутации фермента crispr, уменьшающие нецелевые эффекты
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
EP3666895A1 (en) 2015-06-18 2020-06-17 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3365441A1 (en) 2015-10-22 2018-08-29 The Broad Institute Inc. Type vi-b crispr enzymes and systems
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
CN108367097A (zh) 2015-12-19 2018-08-03 心脏起搏器股份公司 用于可植入医疗装置的生物惰性涂层
EP3405576A4 (en) * 2016-01-19 2019-09-18 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS USING RNA INTERFERENCE FOR KRAS INHIBITION
US11180759B2 (en) 2016-01-19 2021-11-23 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
KR102670601B1 (ko) 2016-04-19 2024-05-29 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
US11286478B2 (en) 2016-04-19 2022-03-29 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
WO2017218787A1 (en) 2016-06-16 2017-12-21 Cardiac Pacemakers, Inc. Hydrophilization and antifouling of enhanced metal surfaces
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
US10799620B2 (en) 2016-07-21 2020-10-13 Board Of Regents Of The University Of Nebraska Ring and tubular structures and methods of synthesis and use thereof
EP3496771B1 (en) 2016-08-09 2023-01-04 Cardiac Pacemakers, Inc. Functionalized peg for implantable medical devices
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
CA3038304A1 (en) 2016-09-28 2018-04-05 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of use thereof
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
KR101949507B1 (ko) * 2016-11-09 2019-02-18 주식회사 삼양바이오팜 Kras를 표적으로 하는 핵산 함유 약제학적 조성물 및 그 제조방법
EP3596207B1 (en) 2017-03-15 2023-12-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
KR20200006054A (ko) 2017-04-12 2020-01-17 더 브로드 인스티튜트, 인코퍼레이티드 신규 타입 vi crispr 오르소로그 및 시스템
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
EP3630060A1 (en) 2017-05-24 2020-04-08 Silenseed Ltd. Compositions and methods for cancer immunotherapy
US11738116B2 (en) 2017-06-09 2023-08-29 Board Of Regents Of The University Of Nebraska Expanded nanofiber structures comprising electrospun nanofibers and a plurality of holes and methods of making and use thereof
WO2019051642A1 (zh) * 2017-09-12 2019-03-21 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
WO2019060393A1 (en) 2017-09-19 2019-03-28 Board Of Regents Of The University Of Nebraska NANOFIBER STRUCTURES AND METHODS OF USE THEREOF
US20200297924A1 (en) * 2017-09-22 2020-09-24 Cochlear Limited Bioactive agent distribution
EP3692152A4 (en) 2017-10-04 2021-12-01 The Broad Institute, Inc. PROCESSES AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND / OR DOMAINS
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020234868A1 (en) 2019-05-17 2020-11-26 Silenseed Ltd. Compositions and methods for reducing perineural invasion and pain
JP7295559B2 (ja) * 2019-06-03 2023-06-21 国立大学法人 奈良先端科学技術大学院大学 キトサン系複合体組成物及びキトサン系複合体の製造方法
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
IT202100021779A1 (it) 2021-08-11 2023-02-11 Plasfer S R L Piastrine trasfettate con sirna e loro usi terapeutici
TR2021017752A2 (tr) * 2021-11-15 2021-12-21 S D Ue Idari Ve Maliis Dai Bas Genelsekreterlik Transdermal- i̇laç salim özelli̇kli̇ yeni̇li̇kçi̇ nanoli̇fli̇ medi̇kal teksti̇l malzemesi̇ üreti̇m yöntemi̇
CN114381421B (zh) * 2022-02-09 2023-08-15 河北医科大学 溶菌酶诱导的小鼠血管平滑肌细胞炎症模型及其建立方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
JPH09124490A (ja) 1995-10-27 1997-05-13 Eisai Co Ltd ヌクレオチド含有製剤
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
WO2001091725A2 (en) 2000-05-31 2001-12-06 Univ Johns Hopkins Biologically useful polyphosphates
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6514193B2 (en) * 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
US6812217B2 (en) 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
EP1604697A1 (en) * 2004-06-09 2005-12-14 J.A.C.C. GmbH Implantable device
CA2583826A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
JPWO2007029361A1 (ja) * 2005-09-02 2009-03-12 武田薬品工業株式会社 短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法
AU2006318212C1 (en) * 2005-11-23 2012-08-30 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
US8936794B2 (en) * 2006-08-25 2015-01-20 The Regents Of The University Of Michigan Conducting polymer nanotube actuators for precisely controlled release of medicine and bioactive molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20090149569A1 (en) * 2007-07-19 2009-06-11 Shastri V Prasad Surface engineering of tissue graft materials for enhanced porosity and cell adhesion

Also Published As

Publication number Publication date
AU2009265170A1 (en) 2010-01-07
WO2010001325A2 (en) 2010-01-07
US8999945B2 (en) 2015-04-07
CN102137658A (zh) 2011-07-27
IL210185A0 (en) 2011-03-31
EP2323630A2 (en) 2011-05-25
US20110195123A1 (en) 2011-08-11
JP2011526619A (ja) 2011-10-13
WO2010001325A3 (en) 2010-12-02
EP2323630B1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
BRPI0910198A2 (pt) composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
BRPI0914387A2 (pt) sistema de tratamento abdominal, método de tratamento de uma cavidade abdominal aberta, e, método de fabricação de um sistema para tratamento de uma cavidade abdominal de um paciente
BRPI0916007A2 (pt) "sistema de tratamento com pressão reduzida dinâmico para tratamento de um local tecidual em um paciente, método de produção de um sistema de tratamento com pressão reduzida dinâmico para tratar um local tecidual em paciente, método para tratamento de um local tecidual em um paciente, e, membro de aplicação de pressão reduzida"
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0822162A8 (pt) método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI0905733A2 (pt) "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BR112012031103A2 (pt) método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI0811845A2 (pt) Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente
BR112012022211A2 (pt) composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto
BRPI0915267A2 (pt) Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
BRPI0909180A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0909048A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI1008974A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0719276A2 (pt) Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]